含氨氯地平10毫克和厄贝沙坦100毫克的复方片剂对高血压患者血压及心血管危险因素的影响。
Effect of combination tablets containing amlodipine 10 mg and irbesartan 100 mg on blood pressure and cardiovascular risk factors in patients with hypertension.
作者信息
Yagi Shusuke, Takashima Akira, Mitsugi Minoru, Wada Toshihiro, Hotchi Junko, Aihara Ken-Ichi, Hara Tomoya, Ishida Masayoshi, Fukuda Daiju, Ise Takayuki, Yamaguchi Koji, Tobiume Takeshi, Iwase Takashi, Yamada Hirotsugu, Soeki Takeshi, Wakatsuki Tetsuzo, Shimabukuro Michio, Akaike Masashi, Sata Masataka
机构信息
Department of Cardiovascular Medicine, Graduate School of Health Biosciences, University of Tokushima, Tokushima, Japan.
Department of Internal Medicine, Shikoku Central Hospital, Shikokuchuo, Japan.
出版信息
Ther Clin Risk Manag. 2015 Jan 12;11:83-8. doi: 10.2147/TCRM.S72299. eCollection 2015.
BACKGROUND
Hypertension is one of the major risk factors for cardiovascular and cerebrovascular disease and mortality. Patients who receive insufficient doses of antihypertensive agents or who are poorly adherent to multidrug treatment regimens often fail to achieve adequate blood pressure (BP) control. The aim of this study was to determine the efficacy of an angiotensin II receptor blocker (ARB) and calcium channel blocker (CCB) combination tablet containing a regular dose of irbesartan (100 mg) and a high dose of amlodipine (10 mg) with regard to lowering BP and other risk factors for cardiovascular disease.
METHODS
We retrospectively evaluated data from 68 patients with essential hypertension whose treatment regimen was changed either from combination treatment with an independent ARB and a low-dose or regular-dose CCB or from a combination tablet of ARB and a low-dose or regular-dose CCB to a combination tablet containing amlodipine 10 mg and irbesartan 100 mg, because of incomplete BP control. Previous treatments did not include irbesartan as the ARB.
RESULTS
The combination tablet decreased systolic and diastolic BP. In addition, it significantly decreased serum uric acid, low-density lipoprotein cholesterol, and increased high-density lipoprotein cholesterol levels, independent of the BP-lowering effect. Treatment with the combination tablet did not affect serum triglycerides, plasma glucose, glycated hemoglobin, serum potassium or creatinine levels, or the urinary albumin excretion rate.
CONCLUSION
The combination tablet containing amlodipine 10 mg and irbesartan 100 mg had a greater BP-lowering effect than an ARB and a low-dose or regular-dose CCB. In addition, the combination tablet had more favorable effects on serum uric acid, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol levels in patients with hypertension.
背景
高血压是心血管和脑血管疾病及死亡的主要危险因素之一。接受降压药物剂量不足或对多药治疗方案依从性差的患者往往无法实现充分的血压（BP）控制。本研究的目的是确定一种含有常规剂量厄贝沙坦（100毫克）和高剂量氨氯地平（10毫克）的血管紧张素II受体阻滞剂（ARB）与钙通道阻滞剂（CCB）联合片剂在降低血压及其他心血管疾病危险因素方面的疗效。
方法
我们回顾性评估了68例原发性高血压患者的数据，这些患者因血压控制不完全，其治疗方案从独立的ARB与低剂量或常规剂量CCB联合治疗或ARB与低剂量或常规剂量CCB的联合片剂改为含有10毫克氨氯地平和100毫克厄贝沙坦的联合片剂。先前的治疗未包括将厄贝沙坦作为ARB。
结果
联合片剂降低了收缩压和舒张压。此外，它显著降低了血清尿酸、低密度脂蛋白胆固醇，并提高了高密度脂蛋白胆固醇水平，且独立于降压效果。联合片剂治疗不影响血清甘油三酯、血糖、糖化血红蛋白、血清钾或肌酐水平，或尿白蛋白排泄率。
结论
含有10毫克氨氯地平和100毫克厄贝沙坦的联合片剂比ARB与低剂量或常规剂量CCB具有更大的降压效果。此外，联合片剂对高血压患者的血清尿酸、低密度脂蛋白胆固醇和高密度脂蛋白胆固醇水平有更有利的影响。
Zotero 插件